TD Cowen analyst Joshua Jennings raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $70 and keeps a Hold rating on the shares. The firm noted the company offered a favorable multiyear outlook at its annual investor day. The company reiterated its 2024 guidance and introduced 2025 guidance that brackets the Street’s current estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $68 from $63 at Canaccord
- Early notable gainers among liquid option names on December 4th
- Edwards Lifesciences sees FY25 adjusted EPS $2.40-$2.50, consensus $2.47
- Edwards Lifesciences backs FY24 constant currency sales growth of 8%-10%
- Edwards Lifesciences price target raised to $88 from $85 at Barclays